Healthcare & Pharmaceutical Awards 2021

44 GHP / Healthcare and Pharmaceutical Awards 2021 , Jul21611 The number of patients suffering fromType 2 Diabetes has been rising sharply for the last three decades. The disease, which also increases the risk of heart attacks, strokes and kidney failure and other complications, can be reversed and sometimes even avoided by restoring insulin resistance to normal levels. The teamat Concenter Biopharma Ltd have a single focus - to stop type 2 diabetes in its tracks. Best Type 2 Diabetes Drug Development Specialists - Middle East Type 2 diabetes is an impairment in the way the body regulates and uses sugar (glucose) as a fuel. This long-term (chronic) condition results in too much sugar circulating in the bloodstream. Eventually, high blood sugar levels can lead to disorders of the circulatory, nervous and immune systems. In type 2 diabetes, there are primarily two interrelated problems at work. Your pancreas does not produce enough insulin — a hormone that regulates the movement of sugar into your cells — and cells respond poorly to insulin and take in less sugar. Type 2 is more common in older adults, but the increase in the number of children with obesity has led to more cases of type 2 diabetes in younger people. Currently, there is no cure for type 2 diabetes! As chronic diseases go, diabetes is one of the most prevalent. Type 2 Diabetes is thought to affect over 463 million people worldwide and the numbers are rising. Over 4000 new cases are diagnosed daily. 12% of global healthcare expenditure is said to be spent on treatment for diabetes, costing a staggering $850 billion per year. Although some people can avoid diabetes by keeping fit and eating a balanced diet, most people need more help. Concenter Biopharma Ltd is developing medication to prevent and treat Type 2 Diabetes. The company, led by CEO and Director, Dror Chevion, is currently conducting a clinical trial on its new drug, Zygosid-50. Dror tells us: “Modern medications for Type 2 Diabetes have improved the control of blood glucose levels and demonstrated a reduction in cardiovascular and renal complications. But we still need an effective therapy against the core problem - insulin resistance. Potentially, Zygosid-50 can reverse the progress of the disease, avoiding the need for insulin treatment and other commonly prescribed medications. It may even become the monotherapy for Type 2 Diabetes.” The trial, which is being conducted at the Sheba Medical Center in Israel, is examining the safety and effectiveness of Zygosid-50 administered by injection. The aim of the injection is to provide a means of glycaemic control for patients with Type 2 Diabetes by restoring the insulin resistance to normal. To date, the medication has shown multiple beneficial effects. These include restoring blood glucose and insulin resistance to normal levels, suppressing the expression of diabetic pro- inflammatory cytokines and replenishing zinc deficiency. The core technology has already been successful in an extensive series of pre-clinical trials developed and conducted mainly by the scientists at the Hebrew University and Hadassah Medical Center in Jerusalem, headed by Prof. Mordechai Chevion, the lead inventor, which is also a Director in the company. So how did Concenter arrive at this point? Starting in 2017, Concenter received the TechConnect Innovation Award in Washington DC. In 2018, Concenter was selected to pitch at several key events including the second and third World Congress on Clinical Trials in Diabetes and the 8th D-Cure Symposium. Subsequent recognition led to Concenter being selected to pitch at Sachs Associates 19th Annual Biotech in Europe Forum. The most significant award to date was when Zygosid-50 was awarded first place at the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in December 2019. The team followed this by successfully “crowd-funding” around $1.25 million dollars to further fund the project in /102020. With global demand in mind, Concenter aims to market Zygosid-50 as quickly as possible. The drug, which will be manufactured in pill form, is expected to inhibit hyperglycaemia, lower LDL cholesterol, help to lower body weight and reduce sight complications such as cataract formation and retinopathy. The strategy to reduce the time and money spent in traditional regulatory routes focused on the FDA 505(b)(2) abbreviated approval pathway and the Expedited Pathways program. The FDA has accepted the company’s approach and Concenter will be applying for Fast Track Designation as soon as appropriate. Contact: Dror Chevion Company: Concenter Biopharma Ltd Web: